Tag: NASDAQ VACC

Business

Arbutus Biopharma Corp (NASDAQ: ABUS) and Vaccitech PLC – ADR (NASDAQ: VACC) Ink Agreement To Treat Patients With Hepatitis B Virus Infection

Arbutus Biopharma Corp (NASDAQ: ABUS) and Vaccitech PLC – ADR (NASDAQ: VACC) have entered into a partnership to carry out a clinical trial. As part of the agreement, the companies will implement therapeutic combinations to treat patients suffering from chronic hepatitis B virus (HBV) infection (CHB). Additionally, patients who are […]